LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PRQR
ProQR Therapeutics N.V.
There isn't enough reported data to score PRQR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRQR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRQR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRQR PE Valuation
PRQR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRQR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect PRQR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus PRQR down 211%.
PRQR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.41 | +$0.06 |
| Q4 2025 | -$0.44 | -$0.08 |
| Q4 2024 | -$0.36 | +$0.03 |
| Q4 2023 | -$0.39 | +$0.62 |
| Q3 2023 | -$0.49 | +$0.63 |
| Q2 2023 | -$0.79 | +$0.20 |
| Q4 2022 | -$1.01 | +$0.06 |
| Q3 2022 | -$1.12 | -$0.05 |
PRQR is still losing money, but far less than before: $0.41 per share over the past year, against $1.51 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
PRQR has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 253% for PRQR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRQR on profitability, with a higher operating margin.
PRQR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.7M | +453% |
| Q4 2025 | $5.2M | +8.8% |
| Q3 2025 | $3.2M | -25% |
| Q2 2025 | $4.2M | -39% |
| Q1 2025 | $5M | +1.6% |
| Q4 2024 | $4.8M | -34% |
| Q3 2024 | $4.3M | +181% |
| Q2 2024 | $7M | +423% |
PRQR's revenue is growing: $18M last quarter, up 253% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -223% | +16 points |
| Q4 2025 | -194% | +40 points |
| Q3 2025 | -392% | -165 points |
| Q2 2025 | -321% | -264 points |
| Q1 2025 | -239% | -58 points |
| Q4 2024 | -234% | +255 points |
| Q3 2024 | -227% | +313 points |
| Q2 2024 | -57% | +674 points |
PRQR's operating margin was −223% last quarter, up 16 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with PRQR at down 130%.
PRQR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42M | -$28.2M |
| Q4 2025 | -$15.4M | -$4.9M |
| Q3 2025 | -$13.8M | -$7.2M |
| Q2 2025 | -$12.8M | -$5.5M |
| Q1 2025 | -$17.8M | -$175.5K |
| Q4 2024 | -$10.5M | -147% |
| Q3 2024 | -$6.6M | +$2.1M |
| Q2 2024 | -$7.2M | +$4.6M |
PRQR has burned cash in almost every quarter: −$84M over the past year, against −$42M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRQR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRQR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +13.6M shares |
| 1 year | +13% | +13.7M shares |
| 3 years | +47% | +38.1M shares |
| 5 years | +137% | +68.8M shares |
| Available history | +206% | +80.1M shares |
PRQR has 119M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRQR Net Leverage
PRQR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRQR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 13.2 | Oversold |
PRQR's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRQR PE vs Healthcare Sector
PRQR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRQR on trend strength, trading above more of its moving averages.
PRQR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.45 | 6.2% below |
| 20 week MA | $1.72 | 21% below |
| 50 week MA | $1.72 | 21% below |
| 100 week MA | $1.91 | 29% below |
| 200 week MA | $2.02 | 33% below |
PRQR is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRQR on returns for 2026, with the stronger performance.
PRQR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.41 | $4.63 | -51% |
| 2021 | $4.63 | $8.20 | +77% |
| 2022 | $8.20 | $2.71 | -67% |
| 2023 | $2.71 | $1.98 | -27% |
| 2024 | $1.98 | $2.79 | +41% |
| 2025 | $2.79 | $2.17 | -22% |
| 2026 YTD | $2.17 | $1.36 | -37% |
PRQR has finished lower in four of the last six years. It's down 37% so far in 2026.